WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that Chief Executive Officer Wes Kaupinen will present at two major investor conferences in September.
The company is scheduled to host a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 p.m. ET. Palvella will also deliver a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 10:30 a.m. ET.
Live webcasts of both presentations will be available through Palvella’s website, with replays accessible for approximately 90 days.
Palvella is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases that currently lack FDA-approved treatments. Its lead candidate, QTORIN™ rapamycin, is under evaluation in a Phase 3 SELVA trial for microcystic lymphatic malformations and a Phase 2 TOIVA trial for cutaneous venous malformations. The therapy remains investigational and has not yet received regulatory approval.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.